LGC acquires Virusys Corporation.

LGC Clinical Diagnostics, a business unit of LGC, today announced the acquisition of Virusys Corporation, a developer and manufacturer of monoclonal antibodies and viral antigens.

Virusys’ monoclonal antibody technologies and virology expertise are highly complementary to LGC Clinical Diagnostics’ existing antigen product portfolio and will enable LGC to provide customers with antibody technologies to accelerate their infectious disease research programmes, including influenza A and B, herpes simplex viruses and varicella zoster, which can cause diseases like chickenpox and shingles.

Bharathi Anekella, Executive Vice President & General Manager of LGC Clinical Diagnostics, said, “We are excited about the additional scientific expertise Virusys will bring to LGC. As a provider of biological materials and viral antigens, this latest acquisition enhances our infectious diseases portfolio, enabling us to become a true centre of excellence for our customers seeking a full-service source for virology-related products and services.”

LGC is actively seeking opportunities to strengthen its customer offering where it supports strategic growth priorities and is aligned to its purpose: Science for a Safer World.

Established in 1997 in Maryland, USA, Virusys has focused on the development of in vitro diagnostics (IVD), proteins and antibodies and built an enviable reputation for innovation, quality, and reliability across its broad customer base.